In conclusion, we found that pretreatment of mice with imatinib (1) increases lung catalase activity; (2) decreases lung oxidant injury, apoptosis, and pulmonary edema; (3) attenuates systemic cytokine expression; and (4) totally prevents mortality in an in vivo, IV LPS model of sepsis and lung injury. The gene discussed is CAT; the disease is Sepsis.